Compare Hewlett Packard Enterprise Co (HPE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs TG Therapeutics Inc — how do they compare? Hewlett Packard Enterprise Co trades at $73.7 (market cap $94.25B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Hewlett Packard Enterprise Co is far larger — about 11.6× TG Therapeutics Inc's market cap, and Hewlett Packard Enterprise Co pays a 0.8% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and TG Therapeutics Inc for 16 Days on average.
| HPE | TGTX | |
|---|---|---|
Market Cap | $94.25B | $8.16B |
Volume | 16,060,854 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $72.12 | $59.06 |
52-Week Low | $20.01 | $26.94 |
Typical Hold Time | 33 Days | 16 Days |
Enterprise Value | $108.28B | $8.37B |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE trades at $73.46, up 1.87% today and near its 52-week high, driven by strong AI infrastructure demand. The stock has a bullish technical signal with moving averages supporting the uptrend. Recent earnings beats, including Q2 2026 EPS of $1.11 versus $0.932 expected, highlight operational strength. A $1.2 billion AI server order from Vultr and raised revenue guidance fuel optimism, though valuation ratios like a P/E of 36.6 suggest premium pricing.
Outlook remains positive with AI-driven growth catalysts, but risks include high valuation and competitive pressures. Analyst consensus is mixed with a $70.35 price target, slightly below current levels. Net income margin compression in 2025 to 0.16% warrants monitoring, though 2026 projections show recovery. The stock's momentum hinges on execution of AI orders and margin expansion.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
